Association Between the Time of Day of Post‐Transplant Cyclophosphamide Administration and Haemorrhagic Cystitis After Allogeneic Haematopoietic Stem Cell Transplantation
Open Access
- 14 October 2026
- journal article
- Published by Wiley in European Journal of Haematology
Abstract
Objective: To evaluate the impact of the time‐of‐day (daytime vs. nighttime) of the infusion of post‐transplantation cyclophosphamide (PTCy) on the occurrence of haemorrhagic cystitis (HC) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (allo‐HSCT). Methods: We conducted a retrospective, single‐centre cohort study including adult allo‐HSCT between January 2014 and December 2022. All patients received PTCy at a dose of 50 mg/kg/day for two consecutive days. Patients were classified according to the timing of the first PTCy dose: daytime (06:00–17:59) or nighttime (18:00–05:59). The primary endpoint was the incidence of Grade II–IV HC. Results: A total of 178 patients were included. Grade II–IV HC occurred in 16.4% and 31.2% of patients following daytime and nighttime administration, respectively (OR 2.31, 95% CI 0.97–5.49; p = 0.079). After adjustment for potential confounders, nighttime administration was associated with higher odds of Grade II–IV HC (adjusted OR 2.82, 95% CI 1.12–7.10; p = 0.028). Grade III–IV HC was more frequent following nighttime administration (4.8% vs. 15.6%; OR 3.68, 95% CI 1.09–12.45; p = 0.043). No significant differences were observed in transplant outcomes. Conclusions: Nighttime administration of PTCy was associated with a numerically higher incidence of Grade II–IV HC, although the unadjusted primary analysis did not reach conventional statistical significance. This association was statistically significant after adjustment for potential confounders. No detectable differences in transplant outcomes were observed. These findings support prospective evaluation of chronomodulated PTCy administration as a simple, potentially modifiable strategy for reducing treatment‐related toxicity after allo‐HSCT.Keywords
This publication has 26 references indexed in Scilit:
- A Clinical Review of the Different Strategies to Minimize Hemorrhagic Cystitis Associated with the Use of Post-Transplantation Cyclophosphamide in an Allogeneic TransplantTransplantation and Cellular Therapy, 2022
- Outpatient haploidentical hematopoietic stem cell transplant using post-transplant cyclophosphamide and incidence of hemorrhagic cystitisHematology, Transfusion and Cell Therapy, 2020
- Timing of Post-Transplantation Cyclophosphamide Administration in Haploidentical Transplantation: A Comparative Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationTransplantation and Cellular Therapy, 2020
- Hemorrhagic Cystitis after Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: Protective Effect of MESNA Continuous InfusionTransplantation and Cellular Therapy, 2020
- Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant CyclophosphamideTransplantation and Cellular Therapy, 2020
- Optimized Timing of Post-Transplantation Cyclophosphamide in MHC-Haploidentical Murine Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2019
- International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International ConsortiumTransplantation and Cellular Therapy, 2016
- Post-Transplant High-Dose Cyclophosphamide for the Prevention of Graft-versus-Host DiseaseTransplantation and Cellular Therapy, 2015
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group ReportTransplantation and Cellular Therapy, 2015
- HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation CyclophosphamideTransplantation and Cellular Therapy, 2008